- Home
- MDWD vs KVAC Comparison
MDWD vs KVAC Comparison
Compare MDWD & KVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- KVAC
- Stock Information
- Founded
- MDWD 2000
- KVAC 2021
- Country
- MDWD Israel
- KVAC United States
- Employees
- MDWD N/A
- KVAC N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- KVAC
- Sector
- MDWD Health Care
- KVAC
- Exchange
- MDWD Nasdaq
- KVAC Nasdaq
- Market Cap
- MDWD 184.8M
- KVAC 212.1M
- IPO Year
- MDWD 2014
- KVAC 2023
- Fundamental
- Price
- MDWD $17.75
- KVAC $11.00
- Analyst Decision
- MDWD Strong Buy
- KVAC
- Analyst Count
- MDWD 1
- KVAC 0
- Target Price
- MDWD $25.00
- KVAC N/A
- AVG Volume (30 Days)
- MDWD 56.9K
- KVAC 15.8K
- Earning Date
- MDWD 11-26-2024
- KVAC 01-01-0001
- Dividend Yield
- MDWD N/A
- KVAC N/A
- EPS Growth
- MDWD N/A
- KVAC N/A
- EPS
- MDWD N/A
- KVAC 0.43
- Revenue
- MDWD $19,720,000.00
- KVAC N/A
- Revenue This Year
- MDWD $10.37
- KVAC N/A
- Revenue Next Year
- MDWD $26.36
- KVAC N/A
- P/E Ratio
- MDWD N/A
- KVAC $25.45
- Revenue Growth
- MDWD N/A
- KVAC N/A
- 52 Week Low
- MDWD $11.04
- KVAC $10.36
- 52 Week High
- MDWD $24.00
- KVAC $11.00
- Technical
- Relative Strength Index (RSI)
- MDWD 53.40
- KVAC 80.29
- Support Level
- MDWD $17.33
- KVAC $10.94
- Resistance Level
- MDWD $18.25
- KVAC $10.99
- Average True Range (ATR)
- MDWD 0.75
- KVAC 0.01
- MACD
- MDWD 0.05
- KVAC 0.00
- Stochastic Oscillator
- MDWD 73.68
- KVAC 100.00
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About KVAC Keen Vision Acquisition Corporation
Keen Vision Acquisition Corp is a blank check company.